Momentum appears solid and constructive, with a clearly favorable trend across multiple time horizons, reflecting a market that continues to value the quality of the pipeline and the future monetization potential. However, this level of interest also implies high expectations for upcoming clinical milestones: the trend remains supportive, but is sensitive to any disappointment regarding the timing, efficacy, or safety of the development candidates.